Cortendo, which is in-licensing and developing therapies for rare endocrine disorders, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
Its stock currently trades on the Norwegian OTC market under the symbol CORT with a market cap of over $300 million.
The Trevose, PA-based company, which was founded in 1996, plans to list on the Nasdaq under the symbol SBBP. Cortendo initially filed confidentially on 6/12/2015. BofA Merrill Lynch and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
